Garri Zmudze Insights

CONTRIBUTED CONTENT

Garri contributes op-eds and original content for leading outlets across web3, health, startups, and more.

Cointelegraph: The future of longevity lies with digital currency visionaries

Healthcare researchers in collaboration with crypto innovators might prove that a longer and healthier lifespan is an attainable reality.

Contributed Content

Cointelegraph: The future of longevity lies with digital currency visionaries

Technology Networks: The impact of funding on longevity research

New funding sources will spark a wave of transformation in early-stage longevity research.

Contributed Content

Technology Networks: The impact of funding on longevity research

Cointelegraph: NFTs: Empowering artists and charities to embrace the digital movement

With many asking what’s next for NFTs, charities and nonprofits are exploring and maximizing their power for charitable giving.

Contributed Content

Cointelegraph: NFTs: Empowering artists and charities to embrace the digital movement

EXPERT COMMENTARY

Garri is a leading voice for trending topics in the field of health and investing.

Labiotech.eu: Gold rush over: What happens to biotech now that venture capital is out of reach?

Garri shares insights on the current state of biotech venture capital, including overvaluations, recent deals, and the impact of events like the SVB collapse.

Expert Commentary

Labiotech.eu: Gold rush over: What happens to biotech now that venture capital is out of reach?

Clinical Leader: Decentralization, it's more than you think

Decentralization encourages transparency, inclusion, and new funding streams for clinical research.

Expert Commentary

Clinical Leader: Decentralization, it's more than you think

Clinical Leader: Future Funding, Trial Success Necessitates Use Of AI

AI is markedly transforming clinical trials, from enhancing predictive capabilities and patient adherence insights to optimizing trial design and expediting drug development.

Expert Commentary

Clinical Leader: Future Funding, Trial Success Necessitates Use Of AI

ANNOUNCEMENT

Stay up-to-date with the latest from Garri and the companies within his realm.

Longevity.Technology: The time is right for specialist Longevity investment

Garri Zmudze, Sergey Jakimov, and Ilya Suharenko launch a new fund for longevity research: LongeVC.

Longevity.Technology: The time is right for specialist Longevity investment

Longevity.Technology: Basepaws acquisition – exploring longevity beyond human health

Garri was an angel investor in pet health company Basepaws. Its acquisition offers promising insights into the future of human longevity.

Longevity.Technology: Basepaws acquisition – exploring longevity beyond human health

ARDD: Decentralized science and blockchain in aging research

Garri explains the Longevity Science Foundation's work as a nonprofit supporting a decentralized and transparent future of longevity research.

ARDD: Decentralized science and blockchain in aging research

ALL RESOURCES

Content at the cutting-edge of health and technology.

Longevity.Technology: The time is right for specialist Longevity investment

Garri Zmudze, Sergey Jakimov, and Ilya Suharenko launch a new fund for longevity research: LongeVC.

Longevity.Technology: The time is right for specialist Longevity investment

Longevity.Technology: Basepaws acquisition – exploring longevity beyond human health

Garri was an angel investor in pet health company Basepaws. Its acquisition offers promising insights into the future of human longevity.

Longevity.Technology: Basepaws acquisition – exploring longevity beyond human health

ARDD: Decentralized science and blockchain in aging research

Garri explains the Longevity Science Foundation's work as a nonprofit supporting a decentralized and transparent future of longevity research.

ARDD: Decentralized science and blockchain in aging research

Forbes: Meet a VC on a mission to support women in longevity

Garri leads LongeVC to invest in diverse founders that will ensure a representative future of longevity and biotech.

Forbes: Meet a VC on a mission to support women in longevity

LongeVC Backs Interface Biosciences for Advancing Inflammatory Disease Drug Development with AI-Enabled Platform

LongeVC invests in Interface Biosciences, securing $3 million for pioneering pharmaceutical development from bacterial natural products, marking a strategic advancement towards critical IND-enabling studies

Expert Commentary

LongeVC Backs Interface Biosciences for Advancing Inflammatory Disease Drug Development with AI-Enabled Platform

LongeVC Supports UNP's $32M Series A Funding for AI-Driven Macrocycle Drug Development

LongeVC Partakes in UNP's $32 Million Series A Funding, Boosting AI-Driven Macrocycle Innovation for Oncology and Beyond

LongeVC Supports UNP's $32M Series A Funding for AI-Driven Macrocycle Drug Development

Garri Zmudze Speaking at The Asia Summit on Global Health (ASGH) in Hong Kong

Garri Zmudze will attend this year’s Asia Summit on Global Health (ASGH 2024) as a speaker and investor. He will participate in the "New Frontiers in Healthy Ageing" panel.

Garri Zmudze Speaking at The Asia Summit on Global Health (ASGH) in Hong Kong

Summary of LongeVC’s Investments in Q1 and Q2

As we’re getting to the end of Q2, we prepared a quick summary of all the new additions to LongeVC’s investment portfolio.

Summary of LongeVC’s Investments in Q1 and Q2

LongeVC’s Q3 & Q4 2024: Investments and Portfolio Updates

LongeVC shares Q3 & Q4 2024 updates, including new investments in Glyphic Bio and Proton Intelligence, as well as key portfolio developments from Turn Bio and Longenesis.

LongeVC’s Q3 & Q4 2024: Investments and Portfolio Updates

BioSpectrum: Seeking the 'fountain of youth'

Garri founded the Longevity Science Foundation to fund the diverse treatments contributing to human longevity.

Expert Commentary

BioSpectrum: Seeking the 'fountain of youth'